Lag time to benefit for preventive therapies.

摘要

In their Viewpoint, Dr Lee and colleagues1 explained why clinicians and guideline panels should move beyond age as a crude marker for life expectancy and compare life expectancy with the earliest time when benefits exceed harms. They also noted that "unlike magnitude of benefit, measures of lag time to benefit are rarely reported."